December 2015December 2015
New Product - Evotaz
Evotaz (atazanavir sulfate + cobicistat) is a fixed dose combination of the HIV‑1 antiviral drug atazanavir sulfate boosted by the pharmacokinetic enhancer cobicistat. Evotaz is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults. Evotaz should not be used with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 or are highly dependent on UGT1A1 for clearance and have narrow therapeutic windows. Coadministration of Evotaz with the following medicines is contraindicated due to the potential for serious and/or life‑threatening events or loss of virological response and possible resistance: α1‑adrenoreceptor antagonist alfuzosin; antiarryhthmics dronedarone, quinidine; antimycobacterials rifabutin, rifampicin, rifapentine; antineoplastic irinotecan; calcium channel blocker bepridil; ergot derivatives dihydroergotamine, ergonovine, ergotamine, methylergonovine; GI motility agent cisapride; herbal product St. John’s wort (Hypericum perforatum); HMG‑CoA reductase inhibitors lovastatin, simvastatin; neuroleptic pimozide; non‑nucleoside reverse transcriptase inhibitors nevirapine, efavirenz; PDE‑5 inhibitors sildenafil and tadalafil for the treatment of pulmonary arterial hypertension; orally administered sedative/hypnotics midazolam, triazolam; and β‑agonist salmeterol. Evotaz is available as a fixed dose combination tablet containing 300 mg atazanavir as atazanavir sulfate and 150 mg cobicistat in packs of 30’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au